S-acetamidomethylcysteine

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: S-acetamidomethylcysteine
• 英文别名: (2S)-2-(acetamidomethylamino)-3-sulfanylpropanoic acid
• 化学式: C₆H₁₂N₂O₃S
• 分子量: 192.239
• InChiKey: PZNOHYAFEHKUJJ-RXMQYKEDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.2
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  79.4
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  O-methanesulfonyl-N-hydroxymethylacetamide 、 DL-半胱氨酸 生成 S-acetamidomethylcysteine
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• [EN] IMMUNOCONJUGATES TARGETING PD-L1<br/>[FR] IMMUNOCONJUGUÉS CIBLANT LE PD-L1
  申请人：BOLT BIOTHERAPEUTICS INC

  公开号：WO2020190734A1

  公开（公告）日：2020-09-24

  The invention provides an immunoconjugate of formula (I) or (II). Antibody-adjuvant immunoconjugates of the invention, comprising an antibody construct that has an antigen binding domain that binds programmed death-ligand 1 (PD-L1) linked to one or more adjuvants, demonstrate superior pharmacological properties over conventional antibody conjugates. The invention further provides compositions comprising and methods of treating cancer with the immunoconjugate.

  该发明提供了公式（I）或（II）的免疫结合物。该发明的抗体-佐剂免疫结合物包括一个抗体构造，其具有结合程序性死亡配体1（PD-L1）的抗原结合结构域，与一个或多个佐剂连接，表现出比传统抗体结合物更优越的药理特性。该发明还提供了包含该免疫结合物的组合物和治疗癌症的方法。
• [EN] IMMUNOCONJUGATES TARGETING CEA<br/>[FR] IMMUNOCONJUGUÉS CIBLANT L'ACE
  申请人：BOLT BIOTHERAPEUTICS INC

  公开号：WO2020190760A1

  公开（公告）日：2020-09-24

  The invention provides an immunoconjugate of formula (I) or (II). Antibody-adjuvant immunoconjugates of the invention, comprising an antibody construct that has an antigen binding domain that binds carcinoembryonic antigen ("CEA") linked to one or more adjuvants, demonstrate superior pharmacological properties over conventional antibody conjugates. The invention further provides compositions comprising and methods of treating cancer with the immunoconjugate.

  该发明提供了式（I）或（II）的免疫结合物。该发明的抗体-佐剂免疫结合物包括一个抗体构建物，其具有结合癌胚抗原（“CEA”）的抗原结合结构域，与一个或多个佐剂连接，表现出比传统抗体结合物更优越的药理特性。该发明还提供了包含该免疫结合物的组合物和治疗癌症的方法。
• [EN] IMMUNOCONJUGATES TARGETING HER2<br/>[FR] IMMUNOCONJUGUÉS CIBLANT LE HER2
  申请人：BOLT BIOTHERAPEUTICS INC

  公开号：WO2020190731A1

  公开（公告）日：2020-09-24

  The invention provides an immunoconjugate of formula (I) or (II). Antibody-adjuvant immunoconjugates of the invention, comprising an antibody construct that has an antigen binding domain that binds human epidermal growth factor receptor 2 ("HER2") linked to one or more adjuvants, demonstrate superior pharmacological properties over conventional antibody conjugates. The invention further provides compositions comprising and methods of treating cancer with the immunoconjugate.

  该发明提供了公式(I)或(II)的免疫结合物。该发明的抗体-佐剂免疫结合物包括一个抗体构建物，具有结合人类表皮生长因子受体2（"HER2"）的抗原结合结构域，与一个或多个佐剂相连，展示出比传统抗体结合物更优越的药理特性。该发明还提供了包含该免疫结合物的组合物和用于治疗癌症的方法。
• [EN] MACROCYCLIC SH2 DOMAIN BINDING INHIBITORS<br/>[FR] INHIBITEURS DE LIAISON DE DOMAINE SH2 MACROCYCLIQUE
  申请人：US GOV HEALTH & HUMAN SERV

  公开号：WO2006039527A1

  公开（公告）日：2006-04-13

  Disclosed are compounds for inhibiting the binding of an SH2 domain-containing protein, for example, a compound of formula (I): FORMULA (I) wherein R1 is a lipophile; R2, in combination with the phenyl ring, is a phenylphosphate mimic group or a protected phenylphosphate mimic group; R3 is, for example, hydrogen, azido, amino, oxalylamino, carboxy alkyl, alkoxycarbonyl alkyl, aminocarbonyl alkyl, or alkyl carbonylamino; R6 is a linker; AA is an amino acid; and n is 1 to 6; or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof. Also disclosed are pharmaceutical compositions and methods of use of such compounds.

  本文披露了用于抑制含有SH2结构域蛋白质结合的化合物，例如，具有以下结构的化合物（I）：FORMULA（I）其中R1是脂溶性基团；R2与苯环结合形成苯磷酸酯模拟基团或受保护的苯磷酸酯模拟基团；R3是，例如，氢、偶氮基、氨基、草酰氨基、羧基烷基、烷氧羰基烷基、氨基羰基烷基或烷基羰基氨基；R6是连接基；AA是氨基酸；n为1至6；或其药学上可接受的盐、立体异构体、溶剂合物或水合物。还披露了包括这些化合物的药物组合物和使用方法。
• Sh2 domain binding inhibitors
  申请人：Burke R. Terrence

  公开号：US20060167222A1

  公开（公告）日：2006-07-27

  Disclosed are compounds for SH2 domain binding inhibition, for example, a compound of formula (I), wherein R 1 is a lipophile; R 2 , in combination with the phenyl ring, is a phenylphosphate mimic group or a protected phenylphosphate mimic group; R 3 is hydrogen, azido, amino, carboxyalkyl, alkoxycarbonylalkyl, aminocarbonylalkyl, or alkylcarbonylamino, wherein the alkyl portion of R 3 may be optionally substituted with a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, aminoalkyl, alkyl, alkoxy, and keto; R 6 is a linker; AA is an amino acid; and n is 1 to 6; or a salt thereof. The conformationally compounds provide enhanced binding affinity with SH2 domain protein. Also disclosed are a pharmaceutical compositions and a method for inhibiting an SH2 domain from binding with a phosphoprotein.

  本发明揭示了用于SH2结构域结合抑制的化合物，例如，式(I)的化合物，其中R1是一个疏水基；R2与苯环结合，是苯基磷酸酯类似物基团或受保护的苯基磷酸酯类似物基团；R3是氢、叠氮基、氨基、羧基烷基、烷氧羰基烷基、氨基羰基烷基或烷基羰基氨基，其中R3的烷基部分可以选择地用来自卤素、羟基、羧基、氨基、氨基烷基、烷基、烷氧基和酮的取代基进行取代；R6是一个连接基；AA是一种氨基酸；n为1至6；或其盐。这些构象化合物提供了与SH2结构域蛋白的增强结合亲和力。本发明还揭示了一种制药组合物和一种抑制SH2结构域与磷酸化蛋白结合的方法。